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Lung cancer therapy with current available chemotherapeutic agents is mainly palliative. For these and other reasons there is
now a great interest to ﬁnd targeted therapies that can be eﬀective not only palliating lung cancer or decreasing treatment-related
toxicity,butalsogivinghopetocurethesepatients.Itisalreadywellknownthattheubiquitin-proteasomesystemlikeothercellular
pathways is critical for the proliferation and survival of cancer cells; thus, proteosome inhibition has become a very attractive
anticancer therapy. There are several phase I and phase II clinical trials now in non-small cell lung cancer and small cell lung
cancer using this potential target. Most of the trials use bortezomib in combination with chemotherapeutic agents. This paper
tends to make a state-of-the-art review based on the available literature regarding the use of bortezomib as a single agent or in
combination with chemotherapy in patients with lung cancer.
1.Introduction
One of the common strategies for cancer therapy is the tar-
geting of cell homeostasis leading to deregulation of cell
processes necessary for survival. In recent years, one of the
novel approaches has been the deregulation of protein hom-
eostasis through the obstruction of intracellular protein
degradation. This has been done by targeting the ubiquitin-
proteasomesystem(UPS).The UPSplaysacentralroleinthe
targeted destruction of cellular proteins, including cell cycle
regulatory proteins. Because these pathways are critical for
the proliferation and survival of all cells, and in particular
cancerous cells, proteasome inhibition is a very attractive
anticancer therapy [1].
The ﬁrst element of this pathway being investigated as a
target is the proteosome. Because the proteasome degrades
about 80% of all intracellular proteins [2], the use of a
proteasome inhibitor triggers a mixed repertoire of tumor-
suppressing and prosurvival pathways in cancer cells [3]. Its
inhibition disturbs the critical intracellular balance between
proapoptotic and antiapoptotic signals shifting it towards
tumor growth inhibition, apoptosis, and decreased metasta-
sis.
The proteasome inhibitor PS-341 (bortezomib), an al-
ready approvedagentforthetreatment ofmultiplemyeloma,
is under evaluation in clinical trials against various ma-
lignancies. Here we will review preclinical and clinical
data involving this novel anticancer mechanism focusing
primarily in the work that has been done in lung cancer.
Bortezomib has beentested as single agent and most recently
in combination with chemotherapeutic and targeted agents.
Multiple targets that directly interact with the proteasome
have been described and may represent future focuses of
more research and possibly therapeutic development.
2.Actionof theUbiquitin-ProteasomeSystem
The UPS regulates many normal cellular processes includ-
ing signal transduction, cell cycle control, transcriptional
regulation, inﬂammation, and apoptosis through protein
degradation [4]. It requires a series of highly regulated and
complexintracellularactivitiesthathavenotbeencompletely2 Journal of Biomedicine and Biotechnology
Table 1: Antitumor and autoprotective mechanisms triggered by
proteasome inhibition. Possible antitumor mechanisms of protea-
some inhibitors.
(i) Accumulation of p53, p21, and p27
(ii) Diﬀerential eﬀects on pro- and antiapoptotic members of
Bcl-2 family
(iii) Downregulation of XIAP and survivins
(iv) Inhibition of inducible NF-κBa c t i v i t y
(v) Accumulation of misfolded proteins and endoplasmic
reticulum stress
(vi) Induction of oxidative stress
(vii) Activation of bone morphogenetic protein signaling
(viii) Inhibition of protein translation
(ix) Inhibition of telomerase activity
(x) Downregulation of PI3 K/Akt signaling
(xi) Upregulation of death receptor
(xii) Histone acetylation
(xiii) Repression of E2F
(xiv) Inhibition of IL-6-mediated signaling
(xv) Suppression of FoxO and FoxMl proteins
(xvi) Tubulin stabilization
(xvii) Induction of mitotic catastrophe
(xviii) Inhibition of epithelial-mesenchymal transition
(xix) Inhibition of angiogenesis
(xx) Immunosensitizationof cancer cells to the cytotoxicity
of lymphocytes
(xxi) Increased genomic instability after exposure to ionizing
radiation
(xxii) Overcoming multidrug resistance by inhibition of
pglycoprotein
Autoregulatory mechanisms against proteasome inhibition
(i) Induction of macroautophagy
(ii) Activation of constitutive NF-κBa c t i v i t y
(iii) Activation of EGFR signaling
(iv) Stat3 phosphorylation
(v) Akt phosphorylation
(vi) Induction of hsp72 and AKR1B10
(vii) Upregulation of glutathione synthesis
Adapted from Wu et al. [3].
elucidated. In general, proteins are targeted for recognition
and for subsequent degradation by the proteasome via the
attachment of multiple ubiquitin molecules. In order to do
this, there are several preparatory steps before proteins are
presented to the proteasome. The ﬁrst step involves the acti-
vation of ubiquitinby the formation ofa thioester bond with
the ubiquitin-activating enzyme (E1) in an ATP-dependent
reaction. Then, E1 delivers the activated ubiquitin to the
E2 ubiquitin-conjugating enzyme. Finally, E3 ligases transfer
ubiquitin from E2 to a lysine residue in the substrate protein
[5]. An ubiquitin chain subsequently forms and presents
the protein to the 26S proteasome. It is important to
note, however, that these preparatory steps are not used
for the degradation of all proteins. Some proteins such as
calmodulinand troponinC undergodegradationbythe pro-
teasome via ubiquitin-independent pathway [6]. Ultimately,
the protein enters the proteasome, ubiquitin is released (if
the protein required preubiquination), and the protein is
degraded.
The degradation of proteins inside the proteasome is
similar to the degradation of proteins by intestinal diges-
tive enzymes. In fact, the proteasome is considered to
have chymotrypsin-like, trypsin-like, and peptidyl-glutamyl
peptide-hydrolyzing- (PHGH-) like activity. The 26S pro-
teasome is a large multicatalytic complex that is comprised
of a 20S core catalytic component (the 20S proteasome)
capped at one or both ends by a 19S regulatory component
[1] .T h e1 9Sl i ds e r v e sa sa ne n t r yp o r t a lf o rt h ep r o t e i n s ,
which are then subjected to adenosine triphosphate (ATP)
hydrolysiswithin thebase.ATPasesunfoldandlinearize large
proteins before they undergo catalysis within the core.
Allosteric interactions guide the intricate sequencing of pro-
teolytic reactions within the core, which ultimately produces
oligopeptides that can be recycled within the cell [6].
3.Bortezomib’s Inhibitionofthe Proteasome
Because peptide boronic acids inhibit serine proteases such
as chymotrypsin by mimicking substrate binding at the
active site, it was postulated that they might inhibit the
proteasome by binding to the chymotrypsin-like site in the
20Score[1].Adamssynthesized 13 boronicacid proteasome
inhibitors and tested them for their ability to inhibit cell
growth against the panel of 60 cell lines from the National
Cancer Institute. One compound, bortezomib, the boronic
acid derivativewhich was later called bortezomib, was potent
and was active against a broad range of cancer cell lines,
including nonsmall cell lung, colon, central nervous system,
melanoma, ovarian, renal, prostate, and breast cancers,
and had a unique cytotoxicity proﬁle, compared with the
NCI’s historical ﬁle of 60,000 compounds [1]. Since the
publicationofthis study in 1999, bortezomib has been tested
in numerous in vitro and in vivo models of several cancers
including NSCLC [6].
4.Resultsofthe Inhibitionof the
Ubiquitin-ProteasomeSystembyBortezomib
Numerous proteins are degraded by the proteasome, so mul-
tiple cellular processes are aﬀected by proteasome inhibition.
Therefore,theactivityofbortezomibindiﬀerentcancersmay
involve a variety of molecular mechanisms (see Table 1)[ 3].
Nevertheless, one protein that has been clearly implicated in
the eﬃcacy of bortezomib is NF-κB.
The proteasome has a direct role in allowing the cell to
progress through the cell cycle by degrading cell cycle regu-
latory proteins and an indirect role by regulating the avail-
ability of transcriptional activators [1]. One transcriptional
a c t i v a t o rb e l i e v e dt oh a v eac e n t r a lr o l ei nm e d i a t i n gm a n y
of the eﬀects of proteasome inhibition is the transcriptional
activatorNF-κB[1].ThistranscriptionalactivatorisinvolvedJournal of Biomedicine and Biotechnology 3
Table 2: In vitro studies with bortezomib.
Carcinoma Cell lines Eﬀects References
Multiple myeloma
MM.1S, MM.1R, Dox40,
MR20, LR5, RPMI8226, IM-9,
U266, ARH-77, Hs Sultan
IkBa degradation, inhibited IL-6-triggered
activation of p42/44 MAPK as well as TNF-a
induced activation of NF-κB,
Hideshima et al., 2001 [7]
Mantle cell
lymphoma
Mino, DB (sp53), Molt-4,
L-428
NF-κB activation, bcl-xL and bﬂ/A1
inhibition, and bcl-2 cleavage Pham et al., 2003 [8]
NSCLC H460, H322, H358, H157,
A549
Cell cycle arrest at G2-M; Bcl-2
phosphorylation and cleavage; p53
stabilization;induction of p21Cip; increase
in cyclins A and B; activation of CDKs;
mitochondrial cytochrome c release;
activation of caspase pathway; apoptosis;
NF-κBD o w n r e g u l a t i o n
Ling et al., 2002 [9],
2003 [10], and 2003 [11];
Denlinger et al., 2004 [12]
Prostate PC-3 (p53 null)
Cell cycle arrest at G2-M; increase in
p21Cip; inhibition of CDK4 activity; PARP
cleavage; apoptosis
Adams et al., 1999 [13]
LNCaP-Pro5 Activation of caspase-3; apoptosis Williams et al., 2003 [14]
Pancreatic MIA-PaCa-2
Enhanced cytotoxic eﬀects of gemcitabine;
reduced NF-κB activation; reduced Bcl-2
expression without aﬀecting Bax or Bak;
PARP cleavage; apoptosis
Bold et al., 2001 [15]
BxPC3 Cell cycle arrest in G0–G1; increase in
p21Cip; caspase-3 activation; apoptosis Shah et al., 2001 [16]
SCCHN UM-SCC-9, UM-SCC-11B
Cell cycle arrest in G2-M and S phases;
increase in p21Cip; apoptosis; (PARP
cleavage shown in murine SCCHN lines);
NF-κBD o w n r e g u l a t i o n
Sunwoo et al., 2001 [17]
Ovarian SKOV 3
Induction of p21Cip; inactivation of Bcl-xL;
Downregulation of XIAP; PARP cleavage;
activation of caspase pathway; apoptosis
Frankel et al., 2000 [18]
Breast MCF-7 Cytotoxicity (molecular markers not
determined) Teicher et al., 1999 [19]
Colorectal LOVO,KM12L4, WiDR
Inhibits chemotherapy-induced NF-κB
activation; enhances chemotherapy-induced
apoptosis; stabilizes p53, p21Cip; p27Kip
Cusack Jr. et al., 2001 [20]
Adapted from Ludwig et al. [21].
in inﬂammatory and immune responses, and its signaling
pathways are implicated in tumor development [1].
This proto-oncogenic NF-κB pathway requires protea-
somal activity. Under normal conditions, NF-κB factors are
retainedinaninactivestateinthecytoplasmbytheinhibitors
of NF-κBs (IκBs). In order to be freed from this inhibition,
IκBs need to be phosphorylated, polyubiquitylated, and deg-
raded by the proteasome. Bortezomib downregulates NF-κB
signaling by blocking IκBd e g r a d a t i o n[ 5], and this seems to
be its prevalent mechanism of action, especially in multiple
myeloma and certain solid tumors [21]. Inhibition of NF-
κB reduces the expression of proinﬂammatory response
genesand upregulatesthecyclin-dependentkinase inhibitors
p21Cip1 and p27Kip1, resulting in increased apoptosis in
tumor cells [5].
Other important ways in which apoptosis is induced by
bortezomib in various models was the induction of phos-
phorylation and subsequent cleavage of the antiapoptotic
factor Bcl-2, the Upregulation of CDK inhibitors, such as
p21Cip, stabilization of p53 [21], and interference with the
unfolded protein response (UPR) leading to endoplasmatic
reticulumstress and thusincreased apoptosis[22].Addition-
ally, bortezomib sensitizes resistant solid tumorcellsto TNF-
likeapoptosis,inducingligand-(TRAIL-)inducedapoptosis,
probably by increasing the levels of death receptors DR4 and
DR5 [23].
5.In Vitro StudiesShowingtheEffectof
Bortezomib inCancer
Extensive preclinical research has been conducted with
bortezomib to elucidate its mechanism of action and to
examine its activity. In cell culture, bortezomib induces
apoptosis in both hematologic and solid tumor malignancies
(see Table 2).
6.ProteasomeInhibitor TargetsinLungCancer
As in part mentioned above, multiple targets of proteasome
inhibition with diﬀerent cellular eﬀects have been identiﬁed,4 Journal of Biomedicine and Biotechnology
among those the very important transcription factor directly
involved in apoptosis resistance and expression of adhesion
molecules is NF-κB. Usually inactive intracellularly due to
binding to IkBα, it becomes activated after exposure to
cytokines, stress, and receptor signaling, leading to apoptosis
resistance, increase in growth factors, angiogenesis, and
possible tumor metastasis. NF-κB activation is blocked via
proteasomeinhibitiondecreasingdownstream signaling thus
decreasing cell survival and growth [17]. Overexpression of
the antiapoptotic protein Bcl-2 leads to chemoresistance;
bortezomib causes downregulation of Bcl-2 via phosphory-
lation in NSCLC [9, 24], as well as decreased transcription
of the Bcl-2 promoter, decreased Bcl-2 level, and induced
apoptosis in SCLC [25]. An upregulation of Bax a proapop-
totic mediator has proven beneﬁcial leading to an increase
beneﬁt from proteasome inhibitor by decreasing Bcl-2/Bax
ratio [15].
Cell cycle arrest in G2M phase can be induced by borte-
zomib in NSCLC which is in part due to accumulation of
P53, which is crucial for transcription of genes involved in
cell cycle and DNA synthesis [36]. The absence of cyclin-
dependentkinaseinhibitorp27actsaspoorprognosticfactor
in NSCLC, bortezomib causes upregulation of p21 and p27
kinaseinhibitorleadingtoarrestofcellcycleinhibitingcyclin
A and cyclin E [10, 24, 36].
Bortezomib has been also shown to enhance tumor
necrosisfactorrelatedapoptosisinducingligand(TRAIL)in-
duced apoptosis in human cancer cells, bortezomib induced
caspase 8 dependent apoptosis, cooperated with trail to
induce apoptosis and up-regulated death receptor 5 (DR5)
expression in NSCLC cells, which correlated with increased
apoptosis by PS-341 and enhancement of TRAIL-induced
apoptosis in NSCLC. On the other hand, c-FLIP and surviv-
ing levels were elevated after exposure to bortezomib, which
in turn protects cells from bortezomib-induced apoptosis
[37].
6.1.PhaseISingle AgentProteasomeInhibitors inLungCancer.
Aghajanian et al. evaluated the safety and pharmacodynamic
behavior of bortezomib in patients with histologically con-
ﬁ r m e ds o l i dt u m o r sw h oh a db e e nh e a v i l yp r e t r e a t e da n d
for which no other therapeutic options were available [38].
Forty-three patients were enrolled after eligibility criteria
were met, and informed consent was signed; patientswith 14
histologicallydiﬀerenttumortypesenteredthestudy;among
those, 8 patients had documented NSCLC. Prior treatment
included a median number of 4 prior chemotherapy reg-
imens, and 12 subjects had received radiation therapy as
primary treatment for their malignancy. Forty-three patients
received a total of 89 cycles of therapy given twice weekly for
2 consecutiveweeks and followed by 1-week recovery period,
doses ranged from 0.13 to 1.56mg/m2/dose (9 dose levels),
with a median number of 2 courses given per patient.
Toxicities were minimal in the ﬁrst ﬁve dose levelgroups;
no hematological dose limiting toxicity was reported, with
an increase in the incidence of thrombocytopenia and neu-
tropenia at higher doses. Dose limiting nonhematological
toxicities were reported and consisted mainly of diarrhea
and painful sensory neuropathy; 2 out of 12 patients treated
at the 1.56/m2 dose developed grade 3 diarrhea and also
another 2 out of 12 patients in the same dose group and
one in a lower dose group (1.30mg/m2) developed grade 3
painful sensory neuropathy which had worsened from prior
preexisting symptoms. Allthesepatientshadbeenexposedto
taxanes and either carboplatin or cisplatin as prior therapies.
Pharmacodynamic studies revealed a dose-related inhi-
bition of 20S proteasome activity at higher doses, no
signiﬁcant diﬀerence in the mean percentage of inhibition
at the 4 diﬀerent dosing days after 1 hour of drug adminis-
tration; complete recovery of proteasome activity to baseline
was evident prior to drug administration on days 4, 8,
and 11 indicating no apparent change to drug sensitivity
towards bortezomib-induced proteasome inhibition. Protea-
some activity also evaluated at 24h after day 1 and day
8 dosing which showed recovery but not back to baseline
values.
One partial response was seen in a patient with NSCLC
who had received prior therapy with six cycles of paclitaxel
and carboplatin, two cycles of gemcitabine, three of mit-
omycin and vinblastine, four weekly docetaxel, and eight
weekly methotrexate doses, with disease progression onall of
the above regimens; a 50% reduction in the size of bilateral
pulmonary nodular inﬁltrate was seen, with a duration of
three months, patient symptoms improved as well, but had
to discontinue treatment after three cycles due to painful
sensory neuropathy.Stablediseasewas seenin3patientswith
other tumor types with a mean duration of 4 months.
Dy et al. conducted another phase I and pharmacologic
trial of two schedules of bortezomib in patients with ad-
vanced cancer [39]; the trial enrolled a total of 44 patients
with multiple diﬀerent tumor types. Of those 2 patients
had lung cancer, most of them consisted of colorectal and
kidneytumorsfollowed bypancreaticand prostatecancer.73
courses of therapy with 6 diﬀerent dose levels (ranging from
0.5 to 1.70mg/m2) were administered; 28 patients received
study treatment twice weekly for 4 out of 6 weeks, but due
to increased toxicity on this schedule, 16 additional patients
received study treatment only twice weekly for 2 out of every
threeweeks.Themediannumberofcoursesgivenperpatient
was 2 in both schedules.
Hematological toxicities related to treatment grade >2
wereanemia andthrombocytopenia,mostofthemoccurring
in schedule one. Reversible thrombocytopenia was dose
limiting for both schedules at 1.60 and 1.70mg/m2 dose,
no bleeding complications were associated with such nor
need for platelet transfusion. Mild leukopenia was observed
in one patient in schedule two. Most nonhematological
toxicities were reported as mild to moderate consisting of
fatigue, diarrhea, nausea, anorexia, sensory neurotoxicity,
rash, and vomiting for schedule one; sensory neurotoxicity
was dose limiting in one patient in this schedule. Similar side
eﬀects were reported in schedule two with the exception of
rash and sensory neuropathy; two cases of grade 3 diarrhea
were reported in schedule two which improved with dose
reductions and the use of loperamide.
Forty-one patients out of the 44 enrolled were assessable
for antitumor activity; partial regression (>50%) of a per-
inephric plasmacytoma was observed in one patient beforeJournal of Biomedicine and Biotechnology 5
cycle 2 of treatment and was sustained for 4 months; ﬁve
patients had stable disease in at least one evaluation. There
was as in the previously described study a dose-dependant
increase in the degree of proteasome inhibition after 1
hour of drug administration with a recovery of proteasome
activity of 85% at 24 hours except in those receiving
1.50mg/m2 on schedule one where a 35% inhibition was still
observed at 24 hours. A 549 human NSCLC cells showed a
marked increase in p53 levels for 24 hours after exposure to
bortezomib.
6.2.PhaseIISingleAgentProteasomeInhibitor inLungCancer.
Stevenson et al. conducted a phase II pharmacodynamic
study using single agent bortezomib in patients with adva-
nced stage NSCLC who had received less or equal to one
prior regimen [40]. 23 patients were enrolled and received
bortezomib at 1.3 to 1.5mg/m2 dosing on days 1, 4, 8 and
11 every 21 days; results revealed one patient having partial
response, and 9 patients had stable disease, lasting more
than 4 cycles in 5 of the patients. Most common grade 3
toxicitiesincludednausea andvomiting,sensory neuropathy,
constipation,rash,andthrombocytopenia.Evaluationofp65
and phosphorylated p65 (pp65) by western blot analysis in
12 patients revealed no change in total p65, the ratio of
p65/pp65 was also unaﬀected across the entire group, but
signiﬁcantly decreased in patients with grade 3 toxicity at
30 minutes with nadir at 4 hours and recovery at 24 hours.
They were unable to achieved clinical signiﬁcance with these
results.
The role of bortezomib was evaluated in relapsed or
refractory extensive stage small cell lung cancer (SCLC)
by Lara et al. in the Southwest Oncology Group (SWOG)
phase II trial (S0327) [41]; 56 patients with histologically or
cytologically conﬁrmed diagnosis or SCLC with evidence of
measurable disease, good performance status, and adequate
end organ function who had received prior platinum con-
tainingregimens and who hadnot receivedpriorbortezomib
were enrolled. Treatment was administered on days 1, 4,
8, and 11 every 21 days at a dose of 1.3mg/m2 with dose
reductions to 1.0mg/m2 if toxicities graded at 3 or 4 based
on the National Cancer Institute Common Toxicity Criteria
(CTC) version 2.0. Primary end point was response rate
(RR); secondary end points included time to progression
(TTP) and overall survival (OS). In terms of sensitivity to
platinum-based therapy, the patients were well distributed:
28 with platinum sensitive (relapse >90 days after platinum)
and 28 with platinum refractory (progression during or < or
equal to 90 after platinum). Partial response was observed
in one patient and stable disease in two patients in the
platinum refractory group; most patients (83%) had disease
progression and/or developed symptomatic deterioration;
early death was observed in one patient on each group.
Three patients were not assessable for response due to other
reasons. Median progression-free survival (PFS) and OS for
the platinum refractory group were 1.1 and 3.1 months,
respectively; in the platinum sensitive group, median PFS
was 1.2 months and OS 2.9 months. The 6-month PFS rate
was 10% and 0% for the platinum refractory and platinum
sensitive group, respectively, and overall 6-month survival
was 25% for both strata. Side eﬀects exceeding grade 2 were
fatigue and thrombocytopenia; one death possibly related to
bortezomib was reported consisting of dyspnea which led
to respiratory failure. Pretreatment samples were analyzed
via immunhistochemistry; two out of eight patients had
abnormally low p27 levels, ﬁve had low BAX levels, and six
had abnormally high Bcl-2. Bcl-xl was abnormally expressed
in a high percentage in all 8 specimens. Patients had at least
two of these markers abnormally expressed in their tumors
with ﬁve patients having 3 proteins abnormally expressed.
These and other studies showed that bortezomib as a
single agent has limited activity with single agent responses
up to 8% only [42].
7.Bortezomib CombinationsinNSCLC
More recently in combination with chemotherapy, borte-
zomib has shown its most encouraging activity [42]. Recent
phase I studies have shown that bortezomib combinations
are generally well tolerated and have little addition in tox-
icity as compared to chemotherapy alone (Table 3). More
importantly, there has been a signiﬁcant increase in survival
observed with the use of bortezomib in combination. Work
from Davies et al. showed that bortezomib plus gemc-
itabine/carboplatin resulted in a notable survival beneﬁt (11
months overall survival) in patients with advanced NSCLC
[32].
Work remains to be done to determine if more combi-
nations of bortezomib with otherchemotherapy regimens or
with targetedtherapieswill yield further survival advantages.
Thus far, results with docetaxel, docetaxel + cetuximab,
pemetrexed, and erlotinib show modest results at best
(Table 3). There are interesting results for example about the
combination of erlotinib and bortezomib. Piperdi et al. [43]
found that in H358 bronchoalveolar cells, the combination
is neither additive nor synergistic in the NSCLC cell lines
studied. The choice of schedule may be very important in
combining erlotinib with bortezomib, and further in vivo
studies are required to further evaluate this combination.
Also there is ongoing research looking for predictive
markers of bortezomib sensitivity. Voortman et al. [44]
showed that the proteasomal as well as apoptotic phenotype
determines bortezomib sensitivity in NSCLC cells. There is a
preclinical rationale to combine proteasome inhibition with
proapoptotic agents as well as agents promoting a more
favorable proteasomal phenotype to overcome this resis-
tance.
8.Conclusion
Ubiquitin-proteasome system is critical for the proliferation
and survival of cancer cells, and its inhibition by proteasome
inhibitors such as bortezomib has become a very attractive
anticancer therapy. Bortezomib has proven to be active
against a broad range of cancer cell lines including NSCLC,
and it has been tested in numerous in vitro and in vivo
NSCLC models. Current phases I and II studies are showing
the possibility to have a new targeted therapy for NSCLC6 Journal of Biomedicine and Biotechnology
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a
n
c
e
r
P
a
t
i
e
n
t
s
w
e
r
e
a
s
s
i
g
n
e
d
t
o
b
o
r
t
e
z
o
m
i
b
1
.
5
m
g
/
m
2
(
a
r
m
A
)
o
r
b
o
r
t
e
z
o
m
i
b
1
.
3
m
g
/
m
2
p
l
u
s
d
o
c
e
t
a
x
e
l
7
5
m
g
/
m
2
(
a
r
m
B
)
.
A
t
r
e
a
t
m
e
n
t
c
y
c
l
e
o
f
2
1
d
a
y
s
c
o
m
p
r
i
s
e
d
f
o
u
r
b
o
r
t
e
z
o
m
i
b
d
o
s
e
s
o
n
d
a
y
s
1
,
4
,
8
,
a
n
d
1
1
,
p
l
u
s
,
i
n
a
r
m
B
,
d
o
c
e
t
a
x
e
l
o
n
d
a
y
1
R
O
R
R
w
e
r
e
8
%
i
n
a
r
m
A
a
n
d
9
%
i
n
a
r
m
B
.
D
C
R
r
a
t
e
s
w
e
r
e
2
9
%
i
n
a
r
m
A
a
n
d
5
4
%
i
n
a
r
m
B
.
M
e
d
i
a
n
T
T
P
w
a
s
1
.
5
m
o
n
t
h
s
i
n
a
r
m
A
a
n
d
4
.
0
m
o
n
t
h
s
i
n
a
r
m
B
.
O
n
e
-
y
e
a
r
s
u
r
v
i
v
a
l
w
a
s
3
9
%
a
n
d
3
3
%
,
a
n
d
O
S
w
a
s
7
.
4
a
n
d
7
.
8
m
o
n
t
h
s
i
n
a
r
m
s
A
a
n
d
B
,
r
e
s
p
e
c
t
i
v
e
l
y
F
a
n
u
c
c
h
i
e
t
a
l
.
2
0
0
6
[
2
7
]
D
o
c
e
t
a
x
e
l
+
C
e
t
u
x
i
m
a
b
R
a
n
d
o
m
i
z
e
d
P
h
a
s
e
I
I
T
r
i
a
l
o
f
D
o
c
e
t
a
x
e
l
P
l
u
s
C
e
t
u
x
i
m
a
b
o
r
D
o
c
e
t
a
x
e
l
P
l
u
s
B
o
r
t
e
z
o
m
i
b
i
n
P
a
t
i
e
n
t
s
w
i
t
h
A
d
v
a
n
c
e
d
N
o
n
s
m
a
l
l
-
C
e
l
l
L
u
n
g
C
a
n
c
e
r
a
n
d
a
P
e
r
f
o
r
m
a
n
c
e
S
t
a
t
u
s
o
f
2
:
C
A
L
G
B
3
0
4
0
2
D
o
c
e
t
a
x
e
l
3
0
m
g
/
m
2
o
n
d
a
y
s
1
,
8
,
a
n
d
1
5
e
v
e
r
y
2
8
d
a
y
s
i
n
c
o
m
b
i
n
a
t
i
o
n
w
i
t
h
e
i
t
h
e
r
c
e
t
u
x
i
m
a
b
4
0
0
m
g
/
m
2
l
o
a
d
i
n
g
d
o
s
e
f
o
l
l
o
w
e
d
b
y
2
5
0
m
g
/
m
2
w
e
e
k
l
y
(
D
+
C
)
o
r
b
o
r
t
e
z
o
m
i
b
1
.
6
m
g
/
m
2
o
n
d
a
y
s
1
,
8
,
a
n
d
1
5
e
v
e
r
y
2
8
d
a
y
s
(
D
+
B
)
f
o
r
u
p
t
o
4
c
y
c
l
e
s
.
P
a
t
i
e
n
t
s
w
i
t
h
r
e
s
p
o
n
d
i
n
g
o
r
s
t
a
b
l
e
d
i
s
e
a
s
e
c
o
n
t
i
n
u
e
d
c
e
t
u
x
i
m
a
b
o
r
b
o
r
t
e
z
o
m
i
b
u
n
t
i
l
p
r
o
g
r
e
s
s
i
o
n
O
R
R
r
e
s
p
o
n
s
e
r
a
t
e
s
w
e
r
e
1
3
.
3
%
a
n
d
1
0
.
3
%
f
o
r
D
+
C
a
n
d
D
+
B
,
r
e
s
p
e
c
t
i
v
e
l
y
.
M
e
d
i
a
n
P
F
S
w
a
s
3
.
4
m
o
n
t
h
s
i
n
t
h
e
D
+
C
a
r
m
a
n
d
1
.
9
m
o
n
t
h
s
i
n
t
h
e
D
+
B
a
r
m
.
6
-
m
o
n
t
h
P
F
S
w
e
r
e
2
7
.
8
%
a
n
d
1
3
.
8
%
a
n
d
5
.
0
a
n
d
3
.
9
m
o
n
t
h
s
f
o
r
m
e
d
i
a
n
s
u
r
v
i
v
a
l
,
r
e
s
p
e
c
t
i
v
e
l
y
.
G
r
a
d
e
3
/
4
h
e
m
a
t
o
l
o
g
i
c
t
o
x
i
c
i
t
y
w
a
s
1
6
%
f
o
r
D
+
C
a
n
d
2
1
%
f
o
r
D
+
B
,
w
h
e
r
e
a
s
n
o
n
h
e
m
a
t
o
l
o
g
i
c
t
o
x
i
c
i
t
i
e
s
w
e
r
e
o
b
s
e
r
v
e
d
i
n
6
3
%
a
n
d
4
4
%
o
f
p
a
t
i
e
n
t
s
,
r
e
s
p
e
c
t
i
v
e
l
y
.
N
e
i
t
h
e
r
c
o
m
b
i
n
a
t
i
o
n
m
e
t
t
h
e
p
r
e
s
p
e
c
i
ﬁ
e
d
P
F
S
e
n
d
p
o
i
n
t
t
o
j
u
s
t
i
f
y
f
u
r
t
h
e
r
r
e
s
e
a
r
c
h
i
n
t
h
i
s
s
e
t
t
i
n
g
L
i
l
e
n
b
a
u
m
e
t
a
l
.
2
0
0
9
[
2
8
]
C
a
r
b
o
p
l
a
t
i
n
+
P
a
c
l
i
t
a
x
e
l
a
n
d
X
R
T
P
h
a
s
e
I
T
r
i
a
l
o
f
C
a
r
b
o
p
l
a
t
i
n
/
P
a
c
l
i
t
a
x
e
l
/
B
o
r
t
e
z
o
m
i
b
a
n
d
C
o
n
c
u
r
r
e
n
t
R
a
d
i
o
t
h
e
r
a
p
y
f
o
l
l
o
w
e
d
b
y
S
u
r
g
i
c
a
l
R
e
s
e
c
t
i
o
n
i
n
S
t
a
g
e
I
I
I
N
o
n
s
m
a
l
l
C
e
l
l
L
u
n
g
c
a
n
c
e
r
B
o
r
t
e
z
o
m
i
b
w
a
s
a
d
m
i
n
i
s
t
e
r
e
d
o
n
d
a
y
s
1
,
4
,
1
5
,
a
n
d
1
8
d
u
r
i
n
g
t
h
e
6
-
w
e
e
k
i
n
d
u
c
t
i
o
n
c
h
e
m
o
r
a
d
i
o
t
h
e
r
a
p
y
.
C
o
h
o
r
t
s
o
f
t
h
r
e
e
p
a
t
i
e
n
t
s
w
e
r
e
e
n
t
e
r
e
d
.
A
l
l
p
a
t
i
e
n
t
s
w
e
r
e
t
o
r
e
c
e
i
v
e
c
o
n
s
o
l
i
d
a
t
i
o
n
c
h
e
m
o
t
h
e
r
a
p
y
w
i
t
h
c
a
r
b
o
p
l
a
t
i
n
A
U
C
=
6
a
n
d
p
a
c
l
i
t
a
x
e
l
2
0
0
m
g
/
m
2
1
2
p
a
t
i
e
n
t
s
i
n
t
h
r
e
e
c
o
h
o
r
t
s
w
e
r
e
e
n
r
o
l
l
e
d
.
T
h
e
a
d
d
i
t
i
o
n
o
f
b
o
r
t
e
z
o
m
i
b
w
a
s
w
e
l
l
t
o
l
e
r
a
t
e
d
,
w
i
t
h
n
o
u
n
e
x
p
e
c
t
e
d
t
o
x
i
c
i
t
i
e
s
d
u
r
i
n
g
t
h
e
i
n
d
u
c
t
i
o
n
p
h
a
s
e
.
H
o
w
e
v
e
r
,
t
h
e
r
e
w
e
r
e
3
p
o
s
t
o
p
e
r
a
t
i
v
e
d
e
a
t
h
s
(
t
w
o
p
n
e
u
m
o
n
i
t
i
s
a
n
d
o
n
e
f
r
o
m
f
a
i
l
u
r
e
o
f
t
h
e
b
r
o
n
c
h
o
p
u
l
m
o
n
a
r
y
ﬂ
a
p
)
.
T
h
e
t
r
i
a
l
w
a
s
h
a
l
t
e
d
a
s
a
c
o
n
s
e
q
u
e
n
c
e
o
f
t
h
e
s
e
t
o
x
i
c
i
t
i
e
s
E
d
e
l
m
a
n
e
t
a
l
.
2
0
1
0
[
2
9
]Journal of Biomedicine and Biotechnology 7
T
a
b
l
e
3
:
C
o
n
t
i
n
u
e
d
.
C
o
m
b
i
n
a
t
i
o
n
S
t
u
d
y
D
o
s
e
/
s
c
h
e
d
u
l
e
R
e
s
u
l
t
s
R
e
f
e
r
e
n
c
e
G
e
m
c
i
t
a
b
i
n
e
+
C
i
s
p
l
a
t
i
n
A
P
a
r
a
l
l
e
l
D
o
s
e
-
E
s
c
a
l
a
t
i
o
n
S
t
u
d
y
o
f
W
e
e
k
l
y
a
n
d
T
w
i
c
e
-
W
e
e
k
l
y
B
o
r
t
e
z
o
m
i
b
i
n
C
o
m
b
i
n
a
t
i
o
n
w
i
t
h
G
e
m
c
i
t
a
b
i
n
e
a
n
d
C
i
s
p
l
a
t
i
n
i
n
t
h
e
F
i
r
s
t
-
L
i
n
e
T
r
e
a
t
m
e
n
t
o
f
P
a
t
i
e
n
t
s
w
i
t
h
A
d
v
a
n
c
e
d
S
o
l
i
d
T
u
m
o
r
s
(
P
h
a
s
e
I
s
t
u
d
y
)
P
a
t
i
e
n
t
s
w
e
r
e
a
s
s
i
g
n
e
d
t
o
i
n
c
r
e
a
s
i
n
g
d
o
s
e
s
o
f
b
o
r
t
e
z
o
m
i
b
d
a
y
s
1
a
n
d
8
(
w
e
e
k
l
y
s
c
h
e
d
u
l
e
)
o
r
d
a
y
s
1
,
4
,
8
,
a
n
d
1
1
(
t
w
i
c
e
-
w
e
e
k
l
y
s
c
h
e
d
u
l
e
)
,
i
n
a
d
d
i
t
i
o
n
t
o
g
e
m
c
i
t
a
b
i
n
e
1
,
0
0
0
m
g
/
m
2
d
a
y
s
1
a
n
d
8
a
n
d
c
i
s
p
l
a
t
i
n
7
0
m
g
/
m
2
d
a
y
1
,
e
v
e
r
y
2
1
d
a
y
s
.
M
a
x
i
m
u
m
o
f
s
i
x
c
y
c
l
e
s
W
e
e
k
l
y
b
o
r
t
e
z
o
m
i
b
1
.
0
m
g
/
m
2
p
l
u
s
g
e
m
c
i
t
a
b
i
n
e
1
,
0
0
0
m
g
/
m
2
a
n
d
c
i
s
p
l
a
t
i
n
7
0
m
g
/
m
2
i
s
t
h
e
r
e
c
o
m
m
e
n
d
e
d
p
h
a
s
e
I
I
s
c
h
e
d
u
l
e
.
O
f
3
4
e
v
a
l
u
a
b
l
e
p
a
t
i
e
n
t
s
,
1
3
a
c
h
i
e
v
e
d
P
R
,
1
7
S
D
,
a
n
d
4
P
D
V
o
o
r
t
m
a
n
e
t
a
l
.
2
0
0
7
[
3
0
]
G
e
m
c
i
t
a
b
i
n
e
+
C
a
r
b
o
p
l
a
t
i
n
T
h
e
P
r
o
t
e
a
s
o
m
e
I
n
h
i
b
i
t
o
r
B
o
r
t
e
z
o
m
i
b
i
n
C
o
m
b
i
n
a
t
i
o
n
w
i
t
h
G
e
m
c
i
t
a
b
i
n
e
a
n
d
C
a
r
b
o
p
l
a
t
i
n
i
n
A
d
v
a
n
c
e
d
N
o
n
s
m
a
l
l
C
e
l
l
L
u
n
g
C
a
n
c
e
r
:
A
C
a
l
i
f
o
r
n
i
a
C
a
n
c
e
r
C
o
n
s
o
r
t
i
u
m
P
h
a
s
e
I
S
t
u
d
y
B
o
r
t
e
z
o
m
i
b
w
a
s
a
d
m
i
n
i
s
t
e
r
e
d
o
n
d
a
y
s
1
,
4
,
8
,
a
n
d
1
1
,
a
f
t
e
r
g
e
m
c
i
t
a
b
i
n
e
o
n
d
a
y
s
1
a
n
d
8
,
a
n
d
c
a
r
b
o
p
l
a
t
i
n
o
n
d
a
y
1
o
f
a
2
1
-
d
a
y
c
y
c
l
e
.
T
h
r
e
e
e
s
c
a
l
a
t
i
n
g
d
o
s
e
l
e
v
e
l
s
w
e
r
e
e
v
a
l
u
a
t
e
d
:
b
o
r
t
e
z
o
m
i
b
1
.
0
m
g
/
m
2
/
g
e
m
c
i
t
a
b
i
n
e
8
0
0
m
g
/
m
2
,
b
o
r
t
e
z
o
m
i
b
1
.
0
m
g
/
m
2
/
g
e
m
c
i
t
a
b
i
n
e
1
0
0
0
m
g
/
m
2
,
a
n
d
b
o
r
t
e
z
o
m
i
b
1
.
3
m
g
/
m
2
/
g
e
m
c
i
t
a
b
i
n
e
1
0
0
0
m
g
/
m
2
,
i
n
c
o
m
b
i
n
a
t
i
o
n
w
i
t
h
c
a
r
b
o
p
l
a
t
i
n
A
U
C
5
.
0
T
h
e
M
T
D
w
a
s
d
e
ﬁ
n
e
d
a
s
b
o
r
t
e
z
o
m
i
b
1
.
0
m
g
/
m
2
,
g
e
m
c
i
t
a
b
i
n
e
1
0
0
0
m
g
/
m
2
,
a
n
d
c
a
r
b
o
p
l
a
t
i
n
A
U
C
5
.
0
.
T
h
e
m
o
s
t
c
o
m
m
o
n
g
r
a
d
e
3
/
4
t
o
x
i
c
i
t
i
e
s
w
e
r
e
t
h
r
o
m
b
o
c
y
t
o
p
e
n
i
a
(
r
a
r
e
l
y
a
s
s
o
c
i
a
t
e
d
w
i
t
h
b
l
e
e
d
i
n
g
)
,
a
n
d
n
e
u
t
r
o
p
e
n
i
a
.
N
i
n
e
o
f
2
6
p
a
t
i
e
n
t
s
(
3
5
%
)
a
c
h
i
e
v
e
d
P
R
,
a
n
d
e
i
g
h
t
p
a
t
i
e
n
t
s
h
a
d
S
D
D
a
v
i
e
s
e
t
a
l
.
2
0
0
8
[
3
1
]
B
o
r
t
e
z
o
m
i
b
P
l
u
s
G
e
m
c
i
t
a
b
i
n
e
/
C
a
r
b
o
p
l
a
t
i
n
A
s
F
i
r
s
t
-
L
i
n
e
T
r
e
a
t
m
e
n
t
o
f
A
d
v
a
n
c
e
d
N
o
n
s
m
a
l
l
C
e
l
l
L
u
n
g
C
a
n
c
e
r
A
P
h
a
s
e
I
I
S
o
u
t
h
w
e
s
t
O
n
c
o
l
o
g
y
G
r
o
u
p
S
t
u
d
y
(
S
0
3
3
9
)
S
t
a
g
e
I
I
I
B
/
I
V
N
S
C
L
C
,
p
e
r
f
o
r
m
a
n
c
e
s
t
a
t
u
s
0
-
1
,
a
n
d
n
o
h
i
s
t
o
r
y
o
f
b
r
a
i
n
m
e
t
a
s
t
a
s
i
s
r
e
c
e
i
v
e
d
u
p
t
o
s
i
x
2
1
-
d
a
y
c
y
c
l
e
s
o
f
g
e
m
c
i
t
a
b
i
n
e
1
0
0
0
m
g
/
m
2
,
d
a
y
s
1
a
n
d
8
,
c
a
r
b
o
p
l
a
t
i
n
a
r
e
a
u
n
d
e
r
c
u
r
v
e
5
.
0
,
d
a
y
1
,
a
n
d
b
o
r
t
e
z
o
m
i
b
1
.
0
m
g
/
m
2
,
d
a
y
s
1
,
4
,
8
,
a
n
d
1
1
1
1
4
p
a
t
i
e
n
t
s
(
5
2
%
a
d
e
n
o
c
a
r
c
i
n
o
m
a
,
8
5
%
s
t
a
g
e
I
V
)
O
S
w
a
s
1
1
m
o
n
t
h
s
;
1
-
y
e
a
r
a
n
d
2
-
y
e
a
r
s
u
r
v
i
v
a
l
r
a
t
e
s
w
e
r
e
4
7
%
a
n
d
1
9
%
,
r
e
s
p
e
c
t
i
v
e
l
y
.
M
e
d
i
a
n
P
F
S
w
a
s
5
m
o
n
t
h
s
;
1
-
y
e
a
r
P
F
S
r
a
t
e
w
a
s
7
%
.
O
R
R
w
a
s
2
3
%
,
a
n
d
D
C
R
r
a
t
e
w
a
s
6
8
%
D
a
v
i
e
s
e
t
a
l
.
2
0
0
9
[
3
2
]
P
e
m
e
t
r
e
x
e
d
P
h
a
s
e
I
S
t
u
d
y
o
f
T
w
o
D
i
ﬀ
e
r
e
n
t
S
c
h
e
d
u
l
e
s
o
f
B
o
r
t
e
z
o
m
i
b
a
n
d
P
e
m
e
t
r
e
x
e
d
i
n
A
d
v
a
n
c
e
d
S
o
l
i
d
T
u
m
o
r
s
w
i
t
h
E
m
p
h
a
s
i
s
o
n
N
o
n
s
m
a
l
l
C
e
l
l
L
u
n
g
C
a
n
c
e
r
T
w
o
s
e
p
a
r
a
t
e
d
o
s
e
-
e
s
c
a
l
a
t
i
n
g
a
r
m
s
(
a
r
m
A
a
n
d
a
r
m
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combining this bortezomib with available chemotherapeutic
agents. Prospective phase III trials are needed to validate the
use of this agent in NSCLC.
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